MLICM
TBPH

Metropolitan Life Insurance Company (MetLife)’s Theravance Biopharma TBPH Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,773
Closed -$24.9K – 1888
2024
Q1 		$24.9K Sell
2,773
-699
-20% -$6.48K ﹤0.01% 1752
2023
Q4 		$39K Hold
3,472
– – ﹤0.01% 1578
2023
Q3 		$30K Hold
3,472
– – ﹤0.01% 1681
2023
Q2 		$35.9K Buy
+3,472
New +$38.3K ﹤0.01% 1621
2023
Q1 		– Sell
-4,078
Closed -$45.8K – 2458
2022
Q4 		$45.8K Hold
4,078
– – ﹤0.01% 1530
2022
Q3 		$41.4K Hold
4,078
– – ﹤0.01% 1587
2022
Q2 		$36.9K Hold
4,078
– – ﹤0.01% 1686
2022
Q1 		$39K Sell
4,078
-8,223
-67% -$80.6K ﹤0.01% 1730
2021
Q4 		$136K Buy
12,301
+4,769
+63% +$41.6K ﹤0.01% 2279
2021
Q3 		$55.7K Buy
+7,532
New +$84.2K ﹤0.01% 2746
2021
Q2 		– Sell
-13,313
Closed -$272K – 2908
2021
Q1 		$272K Sell
13,313
-940
-7% -$17.9K ﹤0.01% 1803
2020
Q4 		$253K Hold
14,253
– – ﹤0.01% 1780
2020
Q3 		$211K Hold
14,253
– – ﹤0.01% 1737
2020
Q2 		$299K Hold
14,253
– – 0.01% 1545
2020
Q1 		$329K Buy
14,253
+352
+3% +$8.81K 0.01% 1305
2019
Q4 		$360K Sell
13,901
-713
-5% -$13.9K 0.01% 1530
2019
Q3 		$285K Hold
14,614
– – ﹤0.01% 1637
2019
Q2 		$239K Hold
14,614
– – ﹤0.01% 1777
2019
Q1 		$331K Hold
14,614
– – 0.01% 1562
2018
Q4 		$374K Buy
14,614
+592
+4% +$16K 0.01% 1398
2018
Q3 		$458K Buy
+14,022
New +$382K 0.01% 1438
2014
Q3 		– Sell
-18,407
Closed -$625K – 2725
2014
Q2 		$625K Buy
+18,407
New +$554K ﹤0.01% 1671

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TBPH Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Theravance Biopharma (TBPH) in Q2 2024, closing a stake of 2,773 shares — an estimated $24.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TBPH in Q2 2014 and held it in 22 quarters. The position peaked at $625K in Q2 2014. 132 funds tracked by Wall St. Rank hold TBPH as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Theravance Biopharma position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,773 Theravance Biopharma shares in Q2 2024, an estimated $24.9K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Theravance Biopharma in Q2 2014 and held it in 22 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Theravance Biopharma position peaked at $625K in Q2 2014.
  • 132 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.